Frontlight ResearchEarly access
Fatty liver disease (MASLD/MASH) trials in Netherlands
11 of 15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Dordrecht, Leiden, Nijmegen, Rotterdam, Tilburg, Uden, Utrecht
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - Phase 3Taking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Amsterdam, Dordrecht, Leiden, Nijmegen, Rotterdam, Tilburg, Utrecht
- Age
- 18 years and over
- People
- 1,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Amsterdam, Rotterdam, Utrecht
- Age
- 18 years to 80 years
- People
- 1,350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Amsterdam, Rotterdam, Tilburg, Utrecht
- Age
- 18 years to 75 years
- People
- 1,800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - Phase 3Not yet taking people in NetherlandsA pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
- Where
- Amsterdam, Rotterdam, Uden
- Age
- 18 years and over
- People
- 382 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 - Phase 3Not yet taking people in NetherlandsA study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
- Where
- Amsterdam, Rotterdam, Uden
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 - Phase 3Taking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Amsterdam, Nijmegen, Rotterdam, 's-Hertogenbosch, Utrecht, Zwolle
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - Phase 3Not yet taking people in NetherlandsA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Amsterdam, Rotterdam, Uden
- Age
- 18 years to 75 years
- People
- 1,250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - Phase 4Taking peopleEffect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
- Where
- Rotterdam
- Age
- 18 years to 75 years
- People
- 70
- Run by
- Carmen Dietvorst
See details and how to joinNCT06845345 · EU 2024-519774-40-00 - No phaseTaking peopleHepatic Gene Response to Intravenous Glucose in Obese Patients With and Without MASLD Undergoing Bariatric Surgery
- Where
- Amsterdam
- Age
- 35 years to 65 years
- People
- 40
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT07326865 - No phaseTaking peopleEffect of Timed-Restricted Eating on Metabolic Health
- Where
- Amsterdam
- Age
- 50 years to 75 years
- People
- 30
- Run by
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT06061042